• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>Rydex Inverse 2x S&P MidCap 400

Rydex Inverse 2x S&P MidCap 400

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. New Data at AAN Reinforce Clinical Benefit of Genentech’s OCREVUS (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis

    New Data at AAN Reinforce Clinical Benefit of Genentech’s OCREVUS (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis

  2. Hermes First-Quarter Sales Rise 13.5% to EUR1.35 Billion

    Hermes First-Quarter Sales Rise 13.5% to EUR1.35 Billion

  3. TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early MS Treatment

    TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early MS Treatment

  4. United States PreK-12 Professional Learning Market 2016-2021 - Research and Markets

    United States PreK-12 Professional Learning Market 2016-2021 - Research and Markets

  5. Genentech to Present New Data at AAN Reinforcing Efficacy and Safety of Newly FDA Approved OCREVUS (Ocrelizumab) in Two Types of Multiple Sclerosis

    Genentech to Present New Data at AAN Reinforcing Efficacy and Safety of Newly FDA Approved OCREVUS (Ocrelizumab) in Two Types of Multiple Sclerosis

  6. Luxury stocks get a lift in Europe, but Stoxx 600 tilts lower

    Luxury stocks get a lift in Europe, but Stoxx 600 tilts lower

  7. National Storage Affiliates Trust Announces First Quarter 2017 Earnings Release and Conference Call

    National Storage Affiliates Trust Announces First Quarter 2017 Earnings Release and Conference Call

  8. A.M. BestTV: Insurers Face a Host of Risks, Led by the 'Risk of Inertia'

    A.M. BestTV: Insurers Face a Host of Risks, Led by the 'Risk of Inertia'

12

©2017 Morningstar Advisor. All right reserved.